Research Alliance CORP Iii

Research Alliance Corporation III (RACC) announced a business combination agreement with Oak Hill Bio, a rare disease therapeutics company, to form Oak Hill Bio, Inc., expected to trade on Nasdaq under OAKH.

Research Alliance Corporation III, a blank check company, filed its quarterly report for the period ended March 31, 2026, detailing its formation activities and upcoming initial public offering.

Research Alliance Corporation III (RACC) has entered into a definitive business combination agreement with OHB Pediatrics Ltd. (Oak Hill Bio) to form a new publicly traded rare disease biotechnology company.

Research Alliance Corporation III has entered into a Business Combination Agreement to acquire OHB Pediatrics Ltd., with an expected closing in the second half of 2026.

Bank of America Corporation has reported beneficial ownership of 503,914 Class A Ordinary Shares, representing 6.5% of the outstanding shares, in Research Alliance Corp III.